Susquehanna International Group
INDP icon

Susquehanna International Group’s Indaptus Therapeutics INDP Stock Holding History

Susquehanna International Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9
Closed -$15K – 10137
2019
Q3 		$15K Sell
9
-127
-93% -$378K ﹤0.01% 9981
2019
Q2 		$1.32M Buy
136
+122
+871% +$1.54M ﹤0.01% 5056
2019
Q1 		$227K Buy
+14
New +$245K ﹤0.01% 7686
2018
Q4 		– Sell
-7
Closed -$84K – 9404
2018
Q3 		$84K Buy
+7
New +$66.5K ﹤0.01% 8666

Other funds holding INDP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.18B AUM 26.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Susquehanna International Group's INDP Position: Q1 2025 in Review

Susquehanna International Group sold out of Indaptus Therapeutics (INDP) in Q1 2025, closing a stake of 637 shares — an estimated $15K sold.

Susquehanna International Group first reported a position in INDP in Q1 2018 and held it in 11 quarters. The position peaked at $1.28M in Q1 2019. 17 funds tracked by Wall St. Rank hold INDP as of Q1 2025.

  • Susquehanna International Group reported no remaining Indaptus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 637 Indaptus Therapeutics shares in Q1 2025, an estimated $15K.
  • Susquehanna International Group first reported a position in Indaptus Therapeutics in Q1 2018 and held it in 11 quarters.
  • Susquehanna International Group's Indaptus Therapeutics position peaked at $1.28M in Q1 2019.
  • 17 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.